IGC Pharma announced on March 18, 2026, it will demonstrate its Agentic Harmonization Assistant (AHA) AI tool at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026 in partnership with the Alzheimer's Disease Data Initiative (ADDI).
AHA automates the integration and analysis of complex biomedical datasets from clinical trials, imaging, and other sources, reducing manual harmonization time from months.
The platform supports IGC's lead drug IGC-AD1 in Phase 2 CALMA trials for agitation in Alzheimer's patients and has harmonized 15 Alzheimer's datasets.
IGC filed utility patent applications on February 26, 2026, covering AHA's architectural framework for standardizing heterogeneous datasets.
AHA advanced to the semi-final round of a competitive AI research evaluation and aims to accelerate discoveries in neurodegenerative diseases.